Immunicum AB (IMMU) Stock Overview

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The company's products also develops ilixadencel, which is in Phase II clinical trial for the treatment of kidney cancer; and Phase II clinical trial to treat gastrointestinal stromal tumors. It has a research collaboration with PCI Biotech Holding ASA for novel cancer vaccination treatment; and with Icahn School of Medicine at Mount Sinai, as well as a collaboration with the Australasian Leukaemia and Lymphoma Group to expand clinical testing of vididencel as maintenance treatment for AML. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.